Clinical Research Directory
Browse clinical research sites, groups, and studies.
Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
Sponsor: Yonsei University
Summary
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.
Key Details
Gender
All
Age Range
19 Years - 84 Years
Study Type
INTERVENTIONAL
Enrollment
900
Start Date
2021-03-23
Completion Date
2028-03-13
Last Updated
2026-01-21
Healthy Volunteers
No
Conditions
Interventions
dual anti-platelet therapy at least 6 months
Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
dual anti-platelet therapy 3months or less
Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
Locations (1)
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
Seoul, South Korea